Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
41.11
+0.20 (+0.49%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
30
31
Next >
Adagio Continues Its Run As Biotech Stocks Moderna, BioNTech Dive On Omicron Threat
November 30, 2021
Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant.
Via
Investor's Business Daily
Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb
November 30, 2021
They're very similar companies on the surface, but one is planning for a big disruption.
Via
The Motley Fool
VIR Stock Pops Amid Renewed Omicron Variant Concerns. Here’s Why.
November 30, 2021
Vir Biotechnology has a Covid-19 treatment that its CEO says will do well against new variants. Amid uncertainty, VIR stock is climbing.
Via
InvestorPlace
Exposures
COVID-19
3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
November 29, 2021
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h...
Via
Benzinga
Exposures
COVID-19
Should You Buy The Dip In Tilray?
November 28, 2021
Tilray’s acquisition strategy could drive its long-term growth. However, the company’s shares have fallen in price significantly over the past six months. Furthermore, considering Tilray’s weak bottom...
Via
Talk Markets
1 High-Yield Dividend Stock Worth Buying Right Now
November 28, 2021
GlaxoSmithKline has been one of the few bright spots in the volatile biopharmaceutical space this year.
Via
The Motley Fool
Exposures
COVID-19
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
November 23, 2021
Pfizer, Inc. (NYSE:PFE) found huge success with its COVID-19 ...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead
November 23, 2021
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market...
Via
Benzinga
Biotech Stocks are Due for a Rally
November 22, 2021
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.
Via
Talk Markets
Friday Markets Coverage
November 19, 2021
Today markets are suffering alongside Austria which locked down against Covid-19 again.
Via
Talk Markets
Exposures
COVID-19
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
November 18, 2021
CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
November 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...
Via
Benzinga
US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B
November 17, 2021
The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment
November 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea...
Via
Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19
November 12, 2021
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered...
Via
Benzinga
GlaxoSmithKline Spotlights Encouraging Data For Anemia Drug
November 08, 2021
GlaxoSmithKline plc (NYSE: GSK) announced positive results from the ASCEND program comprised of five Phase 3 studies assessing daprodustat for anemia due to...
Via
Benzinga
Why Vir Biotechnology Stock Is Sliding Today
November 05, 2021
Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today.
Via
The Motley Fool
Exposures
COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
November 05, 2021
Upgrades For IGM Biosciences Inc (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...
Via
Benzinga
Exposures
COVID-19
Product Safety
Thursday Market Overview
November 04, 2021
If you are an IBM shareholder you now own something new Kyndryl.
Via
Talk Markets
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
November 03, 2021
The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on.
Via
The Motley Fool
GlaxoSmithKline PLC Sets New Annual-High Share Price
November 01, 2021
GlaxoSmithKline PLC (NYSE: GSK) traded today at a new 12-month high of $42.71. Approximately 1.8 million shares have changed hands today, as compared to an average 30-day volume...
Via
Benzinga
No Negative Reaction
October 28, 2021
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today.
Via
Talk Markets
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
GlaxoSmithKline plc (GSK) Q2 2021 Earnings Call Transcript
October 27, 2021
GSK earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
GlaxoSmithKline Drops Research On Otilimab In COVID-19
October 27, 2021
GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years...
Via
Benzinga
Exposures
COVID-19
Glaxo Reports Double-Digit Growth In Q3 Pharma, Vaccine Sales, Updates FY21 Guidance
October 27, 2021
GlaxoSmithKline Plc's (NYSE: GSK) turnover was £9.07 billion in Q3, up 5% Y/Y (actual exchange rate AER), 10% (constant exchange rate CER). Pharmaceuticals...
Via
Benzinga
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.